96. Crohn disease Clinical trials / Disease details

Clinical trials : 2,400 / Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215

18 trials found

diseases per page:

Showing 1 to 10 of 18 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2031200406	27/03/2021	10/03/2021	A Study of JNJ-64304500 as Add-on Therapy in Participants with Active Crohn's Disease	A Phase 2a Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Proof-of-Conce ...	Crohn Disease	Group 1- Standard of Care (SOC) Biological Therapy: Adalimumab: Participants will receive JNJ-643045 ...	Numaguchi Hirotaka	NULL	Not Recruiting	>= 18age old	<= 65age old	Both	70	Phase 2	Canada;France;Germany;Italy;Spain;United States Of America;Japan
2	JPRN-UMIN000043165	2021/02/01	31/01/2021	Safety and efficacy of non-medical switching from originator infliximab to infliximab biosimilarCT-P ...	Safety and efficacy of non-medical switching from originator infliximab to infliximab biosimilarCT-P ...	Crohn's disease, Ulcerative colitis, IBDU	witching from originator infliximab to infliximab biosimilar CT-P13	Fukuoka University Chikushi Hospital	NULL	Pending	Not applicable	Not applicable	Male and Female	220	Not selected	Japan
3	EUCTR2019-003662-40-DE (EUCTR)	18/12/2019	22/10/2019	Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and ...	Prospective, open-label, single-arm, single-center phase IV clinical trial to evaluate efficacy and ...	MedDRA version: 20.1;Level: PT;Classification code 10021972;Term: Inflammatory bowel disease;System ...	Trade Name: Amgevita 40 mg Injektionslösung in einer Fertigspritze INN or Proposed INN: ADALIMUMAB Tra ...	Universitätsklinikum Erlangen	NULL	Not Recruiting			Female: yes Male: yes	82	Phase 4	Germany
4	NCT04131322 (ClinicalTrials.gov)	October 10, 2019	10/10/2019	Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease.	Loss of Response of Adalimumab BiosimilarCompared With the Loss of Response of Adalimumab Original: ...	Crohn Disease;Ulcerative Colitis	Drug: Amgevita 40Mg Solution for Injection;Drug: HUMIRA 40Mg Solution for Injection	Fundación Pública Andaluza para la gestión de la Investigación en Sevilla	NULL	Terminated	18 Years	N/A	All	24	Phase 4	Spain
5	NCT04018599 (ClinicalTrials.gov)	July 15, 2019	11/7/2019	Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS	A Phase I, Randomized, Open-label, Parallel-group Study to Determine the Pharmacokinetics, Safety, a ...	Rheumatoid Arthritis;Polyarticular Juvenile Idiopathic Arthritis;Psoriatic Arthritis;Ankylosing Spon ...	Drug: 40 mg MSB11022	Fresenius Kabi SwissBioSim GmbH	PRA Health Sciences	Completed	18 Years	55 Years	All	216	Phase 1	United States
6	EUCTR2019-000717-37-ES (EUCTR)	27/06/2019	28/06/2019	Loss of response of the Adalimumba biosimilar compared with the original drug	LOSS OF RESPONSE OF THE ADALIMUMAB BIOSIMILARCOMPARED WITH THE LOSS OF RESPONSE OF THE ADALIMUMAB OR ...	Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis;Therapeutic area: Diseases [C] - ...	Trade Name: AMGEVITA® Product Name: AMGEVITA (Adalimumab biosimilar) Trade Name: HUMIRA ® Product Name: ...	Fundación Publica Andaluza para la Gestión de Salud en Sevilla (FISEVI)	NULL	Not Recruiting			Female: yes Male: yes	136	Phase 4	Spain
7	EUCTR2018-004967-30-GB (EUCTR)	30/04/2019	14/01/2019	Inflammatory Bowel Disease (IBD) Reference product (Humira-adalimumab) and BiosimilarProduct (Imrald ...	IBD Reference and Biosimilar adalimumab CroSS over Study - iBaSS	Crohn’s disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]	Trade Name: Imraldi Product Name: Imraldi INN or Proposed INN: adalimumab Trade Name: Humira Product Nam ...	University Hospital Southampton NHS Foundation Trust	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	150	Phase 4	United Kingdom
8	NCT03884439 (ClinicalTrials.gov)	March 18, 2019	4/3/2019	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Crohn's Disease or ...	Infliximab BS for Intravenous Drip Infusion 100 mg Pfizer General Investigation (Crohn's Disease or ...	Crohn's Disease;Ulcerative Colitis	Drug: Infliximab [infliximab biosimilar 3]	Pfizer	NULL	Recruiting	N/A	N/A	All	300		Japan
9	NCT03729674 (ClinicalTrials.gov)	November 26, 2018	11/10/2018	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs	Rheumatoid Arthritis;Ankylosing Spondylitis;Ulcerative Colitis;Crohn's Disease	Drug: Biosimilar;Drug: Originator (legacy) drug	McGill University Health Centre/Research Institute of the McGill University Health Centre	Université de Sherbrooke;Institut de rhumatologie de Montréal;Hospital for Special Surgery, New York ...	Recruiting	18 Years	N/A	All	800		Canada
10	EUCTR2018-001546-33-GB (EUCTR)	11/07/2018	14/05/2018	The effects of switching one drug, used to treat either Ulcerative Colitis (UC) or Crohn’s disease ( ...	IBD Biosimilar to Biosimilar Infliximab Switching Study - iBiSS v1.0	Inflammatory Bowel Disease in particular Crohn's Disease and Ulcerative Colitis MedDRA version: 20.1 ...	Trade Name: Flixabi Product Name: Flixabi INN or Proposed INN: Infliximab	University Southampton Hospital NHS Foundation Trust	NULL	Not Recruiting			Female: yes Male: yes	200	Phase 4	United Kingdom

First Previous1 2Next Last